Biogen Halts Plans to Develop Tysabri for Stroke After Phase IIb Trial Flop Post author:Sam Post published:February 6, 2018 Post category:BioPharma Natalizumab did not demonstrate improvement in clinical outcomes compared to placebo. Source: BioSpace You Might Also Like Prometic Snags Rare Pediatric Disease Designation from the FDA for its Inter-Alpha-Inhibitor-Prot… March 4, 2018 Exactech Goes Private in $625M Deal With TPG Capital October 22, 2017 Merck & Co. CEO Resigns From American Manufacturing Council by Tweet August 13, 2017
Prometic Snags Rare Pediatric Disease Designation from the FDA for its Inter-Alpha-Inhibitor-Prot… March 4, 2018
